Study Compares Timing of Hormonal Therapy for Prostate Cancer

<p>SUNDAY, Jun 3 (HealthDay News) Men with metastatic prostate
cancer who bear hormone-deprivation therapy infrequently take breaks from
the diagnosis to minimize a mostly formidable side effects.
However, a vital new investigate that tracked some-more than 1,500 organisation for almost
a decade finds that opting for few diagnosis might take a fee on
certain patients, in terms of condensed survival.
The investigate found that for organisation with cancer involving minimal spread,
adopting a stop-and-start diagnosis report was compared with a
two-year decrease in presence compared to organisation whod been treated on a
continuous basis.
This opening in presence did not seem for organisation whose prostate tumors
showed some-more endless spread, though a researchers stopped brief of
recommending few diagnosis for this subset of patients, pending
better data.
The study, saved by a U.S. National Cancer Institute, was reported
Sunday during a annual assembly of a American Society o...